- Home
- LLYVK vs RYTM Comparison
LLYVK vs RYTM Comparison
Compare LLYVK & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LLYVK | RYTM |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | LLYVK | RYTM |
|---|---|---|
| Price | $81.46 | $103.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $129.92 |
| AVG Volume (30 Days) | 414.8K | ★ 607.6K |
| Earning Date | 02-27-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $11,218,000.00 | ★ $174,334,000.00 |
| Revenue This Year | N/A | $47.98 |
| Revenue Next Year | $8.73 | $56.07 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 54.92 |
| 52 Week Low | $60.55 | $45.91 |
| 52 Week High | $102.62 | $122.20 |
Technical Indicators
Market Signals| Indicator | LLYVK | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 50.76 |
| Support Level | $78.68 | $103.17 |
| Resistance Level | $87.71 | $110.93 |
| Average True Range (ATR) | 3.09 | 4.74 |
| MACD | -0.26 | 0.27 |
| Stochastic Oscillator | 46.55 | 58.38 |
Price Performance
Historical ComparisonAbout LLYVK Liberty Media Corporation
Liberty Live Group would be engaged in the operations of Live Nation, and Liberty Media's planning for that group is to maximize the value of its investment in that company and the other assets attributed to the Liberty Live Group and to use the new Liberty Live common stock to make strategic acquisitions or for other capital raising initiatives.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.